India's pharmaceutical market witnessed a robust 9% month-on-month growth in February, driven by strong performance in cardiology and anti-infective therapies. However, the respiratory segment saw negative growth in both value and units. The growth was primarily attributed to price increases and new product launches. Antibiotic Augmentin retained its position as the top-selling drug, with other key players including Rosuvas, Thyronorm, Liv 52, and Pan. Anti-diabetic drug Rybelsus continued its triple-digit growth trend.